These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 1446408)

  • 21. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis.
    Parthasarathy S; Steinberg D; Witztum JL
    Annu Rev Med; 1992; 43():219-25. PubMed ID: 1580586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice.
    Tsujita M; Tomimoto S; Okumura-Noji K; Okazaki M; Yokoyama S
    Biochim Biophys Acta; 2000 May; 1485(2-3):199-213. PubMed ID: 10832100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice.
    Bird DA; Tangirala RK; Fruebis J; Steinberg D; Witztum JL; Palinski W
    J Lipid Res; 1998 May; 39(5):1079-90. PubMed ID: 9610776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high-density lipoproteins through a phospholipase A2-dependent mechanism.
    Blache D; Gautier T; Tietge UJ; Lagrost L
    FASEB J; 2012 Feb; 26(2):927-37. PubMed ID: 22042222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probucol does not affect lipoprotein metabolism in macrophages of Watanabe heritable hyperlipidemic rabbits.
    Nagano Y; Kita T; Yokode M; Ishii K; Kume N; Otani H; Arai H; Kawai C
    Arteriosclerosis; 1989; 9(4):453-61. PubMed ID: 2751475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of biologically modified low-density lipoprotein in atherosclerosis.
    Carew TE
    Am J Cardiol; 1989 Oct; 64(13):18G-22G. PubMed ID: 2679026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Modified low-density lipoprotein].
    Yoshida H; Nakamura H
    Nihon Rinsho; 1994 Dec; 52(12):3090-5. PubMed ID: 7853694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of high density lipoproteins in the regression of atherosclerosis.
    Badimon JJ; Fuster V; Badimon L
    Circulation; 1992 Dec; 86(6 Suppl):III86-94. PubMed ID: 1424054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probucol inhibits oxidative modification of low density lipoprotein.
    Parthasarathy S; Young SG; Witztum JL; Pittman RC; Steinberg D
    J Clin Invest; 1986 Feb; 77(2):641-4. PubMed ID: 3944273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification.
    Nagano Y; Arai H; Kita T
    Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6457-61. PubMed ID: 1862074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid disorders and their relevance to outcomes in chronic kidney disease.
    Vaziri ND; Norris K
    Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Covalent binding of oxidized cholesteryl esters to protein: implications for oxidative modification of low density lipoprotein and atherosclerosis.
    Kawai Y; Saito A; Shibata N; Kobayashi M; Yamada S; Osawa T; Uchida K
    J Biol Chem; 2003 Jun; 278(23):21040-9. PubMed ID: 12663661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
    Reaven PD; Parthasarathy S; Beltz WF; Witztum JL
    Arterioscler Thromb; 1992 Mar; 12(3):318-24. PubMed ID: 1547191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881.
    Feldman DL; Mogelesky TC; Sharif R; Sawyer WK; Jeune M; Hu CW; Leonards KS; Prescott MF
    Atherosclerosis; 1999 Jun; 144(2):343-55. PubMed ID: 10407495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of probucol on the levels, structure, composition and metabolism of plasma lipoprotein in rats.
    Eisenberg S
    Biochim Biophys Acta; 1993 Mar; 1167(1):79-84. PubMed ID: 8461336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
    Kita T; Nagano Y; Yokode M; Ishii K; Kume N; Ooshima A; Yoshida H; Kawai C
    Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5928-31. PubMed ID: 3475709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of probucol on cholesterol metabolism in mouse peritoneal macrophages: inhibition of HDL-mediated cholesterol efflux.
    Takemura T; Sakai M; Matsuda H; Matsumura T; Biwa T; Anami Y; Nishikawa T; Sasahara T; Shichiri M
    Atherosclerosis; 2000 Oct; 152(2):347-57. PubMed ID: 10998462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis.
    Nofer JR; Brodde MF; Kehrel BE
    Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):726-35. PubMed ID: 20337657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probucol reduces renal injury in the ExHC rat.
    Hattori M; Ito K; Kawaguchi H; Yamaguchi Y
    Nephron; 1994; 67(4):459-68. PubMed ID: 7969681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of probucol on the in vivo plasma clearance of human low density lipoproteins in rabbits and on the expression of lipoprotein receptors in vitro.
    Trezzi E; Roma P; Bernini F; Fumagalli R; Catapano AL
    Atherosclerosis; 1984 Sep; 52(3):309-16. PubMed ID: 6093829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.